As the Australian market shows signs of recovery with a significant 101-point advance, optimism is building around the potential resolution of Middle East tensions and its positive impact on global indices. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, aligning well with investor interests during times of economic uncertainty.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Torque Metals (ASX:TOR) 18.6% 94.2% Magnetic Resources (ASX:MAU) 33.6% 124.2% Image Resources (ASX:IMA) 20.6% 148.6% Forrestania Resources (ASX:FRS) 32.5% 102.3% Fenix Resources (ASX:FEX) 19.7% 64.7% Echo IQ (ASX:EIQ) 19.6% 109.4% Cyclopharm (ASX:CYC) 10.4% 117.1% Clinuvel Pharmaceuticals (ASX:CUV) 10.3% 27.1% Austral Resources Australia (ASX:AR1) 18.3% 39.1% Adveritas (ASX:AV1) 17.9% 109.9%

Click here to see the full list of 114 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Develop Global

Simply Wall St Growth Rating: ★★★★★☆

Overview: Develop Global Limited, with a market cap of A$1.54 billion, is involved in the exploration and development of mineral resource properties in Australia through its subsidiaries.

Operations: The company's revenue comes primarily from its Mining Services segment, which generated A$278.30 million.

Insider Ownership: 20.2%

Develop Global has shown significant growth potential, with earnings expected to increase by 48.5% annually over the next three years, outpacing the Australian market's 11.9% growth forecast. The company's revenue is also projected to grow at a robust 37.9% per year, well above the market average of 6%. Recent earnings results for December 2025 demonstrated strong sales growth from A$113.02 million to A$170.53 million year-over-year, highlighting its expanding operations despite low Return on Equity projections and high non-cash earnings levels.

Click here and access our complete growth analysis report to understand the dynamics of Develop Global. Insights from our recent valuation report point to the potential undervaluation of Develop Global shares in the market.ASX:DVP Ownership Breakdown as at Apr 2026

HMC Capital

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HMC Capital Limited, along with its subsidiaries, operates by owning and managing real estate-focused funds in Australia, with a market capitalization of A$1.12 billion.

Operations: The company's revenue is derived from segments including Digital at A$48.90 million, Real Estate at A$83.30 million, and Private Credit at A$41.80 million.

Story Continues

Insider Ownership: 13.3%

HMC Capital is forecast to grow its revenue at 10.8% annually, surpassing the Australian market's growth rate of 6%. However, its Return on Equity is expected to be low at 6.8% in three years. Despite trading below fair value and projected profitability within three years, recent earnings show a decline with sales dropping from A$127.3 million to A$95.5 million year-over-year, and net income falling significantly from A$166.9 million to A$17 million.

Take a closer look at HMC Capital's potential here in our earnings growth report. Upon reviewing our latest valuation report, HMC Capital's share price might be too optimistic.ASX:HMC Earnings and Revenue Growth as at Apr 2026

PolyNovo

Simply Wall St Growth Rating: ★★★★★☆

Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices across several countries including Australia, New Zealand, the United States, and others, with a market cap of A$690.84 million.

Operations: The company's revenue of A$139.49 million is derived from the development, manufacturing, and commercialisation of the NovoSorb technology.

Insider Ownership: 10.5%

PolyNovo demonstrates strong growth potential with its earnings forecast to increase by 37.24% annually, outpacing the Australian market's 11.9%. Despite a recent dip in net income from A$3.34 million to A$0.003 million for H1 2026, revenue rose to A$74.98 million from A$59.89 million year-over-year. Insider confidence is evident with more shares bought than sold recently, and the stock trades at a discount of 31.8% below estimated fair value, enhancing its appeal as a growth investment opportunity in Australia’s healthcare sector.

Dive into the specifics of PolyNovo here with our thorough growth forecast report. The valuation report we've compiled suggests that PolyNovo's current price could be inflated.ASX:PNV Earnings and Revenue Growth as at Apr 2026

Taking Advantage

Reveal the 114 hidden gems among our Fast Growing ASX Companies With High Insider Ownership screener with a single click here. Ready To Venture Into Other Investment Styles? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:DVP ASX:HMC and ASX:PNV.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments